title: Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.
abstract: The purpose of this study is to investigate whether gene polymorphisms of the vascular endothelial growth factor A (VEGF-A) and its receptor (VEGFR-2) have a pharmacogenetics effect on the anti-VEGF treatment for neovascular age-related macular degeneration (nAMD).
  
  
  
  We carried out a meta-analysis focusing on the relationship between VEGF-related gene polymorphisms and treatment response of nAMD.
  
  
  
  For the single nucleotide polymorphisms (SNPs) withinVEGF-AandVEGFR-2, anti-VEGF treatment was much more effective in patients with nAMD having rs833061 (CC vs TT:OR=2.222, 95% CI 1.252 to 3.944, p=0.006; CT vs TT: OR=2.537,95% CI 1.478 to 4.356, p=0.001 and CC vs CT+TT: OR=2.362, 95% CI 1.414 to 3.946, p=0.001), particularly for Asians (CC vs TT: OR=2.903, 95% CI 1.150 to 7.330, p=0.024; CT vs TT: OR=3.849, 95% CI 1.522 to 9.733, p=0.004 and CC vs CT+TT: OR=3.339, 95% CI 1.369 to 8.145, p=0.008, respectively). In subgroup analysis, rs833061 was more likely to be a predictor of response to anti-VEGF therapy specifically when ranibizumab (RBZ) only regime was adopted or visual acuity (VA) was taken as the standardised assessment of outcome. No association with response to anti-VEGF treatment was detected for the other eight polymorphisms.
  
  
  
  Pharmacogenetics ofVEGF-Apolymorphism rs833061 may play a positive role in response to anti-VEGF therapy for nAMD.
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Mingxing
authors.initials: M
authors.lastname: Wu
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.|Department of Ophthalmology, Chongqing General Hospital, Chongqing, China.
authors.forename: Haibo
authors.initials: H
authors.lastname: Xiong
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Xiong
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Hongmi
authors.initials: H
authors.lastname: Zou
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Minming
authors.initials: M
authors.lastname: Zheng
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Xiuqing
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Xiyuan
authors.initials: X
authors.lastname: Zhou
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D020641:Polymorphism, Single Nucleotide / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics* / Q000378:metabolism; D057135:Wet Macular Degeneration / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2
keywords: Angiogenesis; Drugs; Macula; Neovascularisation; Pharmacology